PMID- 34855694
OWN - NLM
STAT- MEDLINE
DCOM- 20220131
LR  - 20230925
IS  - 1473-6578 (Electronic)
IS  - 0951-7367 (Linking)
VI  - 35
IP  - 1
DP  - 2022 Jan 1
TI  - Psychedelic medicines for mood disorders: current evidence and clinical 
      considerations.
PG  - 22-29
LID - 10.1097/YCO.0000000000000759 [doi]
AB  - PURPOSE OF REVIEW: Despite advances in treatment modalities for mood disorders 
      over recent decades, further therapeutic options are still required. Increased 
      research is occurring, with the pursuit of psychedelic-based pharmacotherapies 
      for a range of mood disorders and other conditions. RECENT FINDINGS: Serotonergic 
      psychedelics have been found to modulate brain networks underlying various 
      psychiatric disorders, as well promoting neurogenesis and neuroplasticity. 
      Randomized placebo-controlled trials have found psilocybin with psychological 
      support effective at treating depression, including treatment-resistant 
      depression; with emergent research also signalling 
      N,N-dimethyltryptamine/ayahuasca also as a potential option for the treatment of 
      depression. Lysergic acid diethylamide has been found to have anxiolytic effects, 
      whereas 3,4-methylenedioxymethamphetamine (MDMA) has been used effectively to 
      treat post-traumatic stress disorder (PTSD), with Phase III clinical trial 
      evidence. Microdosing of psychedelics is a growing phenomenon that has shown 
      benefits in some preclinical data; however, a recent self-directed controlled 
      trial reported no evidence of improved mood. SUMMARY: Current research with 
      medicinal psychedelics, usually as an adjunct to psychotherapy, has shown 
      encouraging results in treating mood disorders. However, there are challenges 
      regarding blinding and sample sizes remain small, and there have been no 
      definitive Phase III studies (aside from MDMA for PTSD). Further work exploring 
      novel formulations, interface with pharmacogenomics and the microbiome, and 
      inflammatory pathways can be advised.
CI  - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Sarris, Jerome
AU  - Sarris J
AD  - Psychae Institute, Melbourne, Victoria.
AD  - NICM Health Research Institute, Western Sydney University, Westmead, New South 
      Wales.
AD  - Florey Institute of Neuroscience and Mental Health, Parkville.
AD  - The Melbourne Clinic Professorial Unit, Department of Psychiatry, University of 
      Melbourne, Melbourne, Victoria, Australia.
FAU - Pinzon Rubiano, Diego
AU  - Pinzon Rubiano D
AD  - Psychae Institute, Melbourne, Victoria.
FAU - Day, Kimberley
AU  - Day K
AD  - Psychae Institute, Melbourne, Victoria.
FAU - Galvao-Coelho, Nicole L
AU  - Galvao-Coelho NL
AD  - NICM Health Research Institute, Western Sydney University, Westmead, New South 
      Wales.
AD  - Laboratory of Hormone Measurement, Department of Physiology and Behavior.
AD  - Postgraduate Program in Psychobiology and Department of Physiology and Behavior, 
      Federal University of Rio Grande do Norte, Natal, Brazil.
FAU - Perkins, Daniel
AU  - Perkins D
AD  - Psychae Institute, Melbourne, Victoria.
AD  - University of Melbourne.
AD  - Centre for Mental Health, Swinburne University of Technology, Melbourne, 
      Victoria, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Curr Opin Psychiatry
JT  - Current opinion in psychiatry
JID - 8809880
RN  - 0 (Hallucinogens)
RN  - 2RV7212BP0 (Psilocybin)
RN  - 8NA5SWF92O (Lysergic Acid Diethylamide)
SB  - IM
MH  - *Hallucinogens/therapeutic use
MH  - Humans
MH  - Lysergic Acid Diethylamide/therapeutic use
MH  - Mood Disorders/drug therapy
MH  - Psilocybin/therapeutic use
MH  - Psychotherapy
EDAT- 2021/12/03 06:00
MHDA- 2022/02/01 06:00
CRDT- 2021/12/02 17:25
PHST- 2021/12/02 17:25 [entrez]
PHST- 2021/12/03 06:00 [pubmed]
PHST- 2022/02/01 06:00 [medline]
AID - 00001504-202201000-00005 [pii]
AID - 10.1097/YCO.0000000000000759 [doi]
PST - ppublish
SO  - Curr Opin Psychiatry. 2022 Jan 1;35(1):22-29. doi: 10.1097/YCO.0000000000000759.